GENova to file for Prostaganin patents in the US and in Europe

Sep 14 2009

GENova Biotherapeutics Inc. ("GENova") today announced that it is preparing for patent application filings in both the US (at the FDA (U.S. Food and Drug Administration (www.fda.gov) for a 510(k) submission) and in Europe through EMEA (European Medicines Agency) subsequent to expected efficacious and non-toxic pre-clinical results for Prostaganin.

Prostaganin: Peptide for prostate cancer

For humans, one of the peptides' most important qualities is the ability to demonstrate complete inhibition of growth of prostate tumour xenografts. Furthermore, they can markedly reduce the secretion of the prostate-specific antigen (PSA), a biomarker widely known to be indicative of this malignancy. Therefore, GENova's Prostaganin is a candidate for development of an anti-cancer medicament for treatment of humans.

Representing the most commonly diagnosed non-cutaneous cancer in ageing males, prostate cancer is the second leading cause of death in North American men. At present, the anti-androgen and LHRH analog drug classes dominate the market. However, with the development of a number of innovative therapies entering the market for the first time, the prostate cancer market will enter a more dynamic and high growth phase. By now, the market for prostate cancer therapies amounts to US$1.5 billion (Drugresearcher.com). But as newer and more innovative therapies are applied, the market is set to experience double digit growth and GENova wants to participate in this rapidly growing market.